Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials-Reference-Cited by-同舟云学术

Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials

Published:2021-10 Issue: Volume:240 Page:73-80
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Cotter Gad,Davison Beth A.,Edwards Christopher,Senger Stefanie,Teerlink John R.,Zannad Faiez,Nielsen Olav Wendelboe,Metra Marco,Mebazaa Alexandre,Chioncel Ovidiu,Greenberg Barry H,Maggioni Aldo P,Ertl Georg,Sato Naoki,Cohen-Solal Alain

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference26 articles.

1. Investigators E-RO. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes;Zinman;N Engl J Med,2015

2. Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction;McMurray;N Engl J Med,2019

3. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes;Neal;N Engl J Med,2017

4. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy;Perkovic;N Engl J Med,2019

5. Perkovic V. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups;Mahaffey;Circulation,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials;Journal of Clinical Lipidology;2024-07

2. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Events, Stroke, and Mortality in Patients with Type 2 Diabetes;Cardiovascular Drugs and Therapy;2022-08-26